Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BONNASDAQ:HEPANASDAQ:PTPINASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBONBon Natural Life$1.26-8.0%$1.55$1.14▼$73.75$210K-0.471.03 million shs345,300 shsHEPAHepion Pharmaceuticals$0.07-6.4%$0.15$0.04▼$56.00$767K1.581.31 million shs97,641 shsPTPIPetros Pharmaceuticals$0.04+6.0%$0.23$0.02▼$16.25$1.10M1.573.14 million shs605,999 shsREVBRevelation Biosciences$0.76-7.4%$1.97$0.74▼$56.00$790K-0.09368,618 shs436,775 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBONBon Natural Life-8.03%-16.00%-25.00%-56.55%-97.73%HEPAHepion Pharmaceuticals-6.40%-12.25%+8.00%-85.38%-99.87%PTPIPetros Pharmaceuticals+5.99%+24.65%-6.60%-98.35%-99.68%REVBRevelation Biosciences-7.44%+1.74%-60.67%-71.89%-97.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBONBon Natural LifeN/AN/AN/AN/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals0.2805 of 5 stars0.03.00.00.01.10.00.6PTPIPetros Pharmaceuticals1.1163 of 5 stars0.05.00.00.02.00.80.6REVBRevelation Biosciences0.6234 of 5 stars0.02.00.00.02.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBONBon Natural Life 0.00N/AN/AN/AHEPAHepion Pharmaceuticals 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBONBon Natural Life$23.84M0.01$1.62 per share0.78$37.78 per share0.03HEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/APTPIPetros Pharmaceuticals$5.11M0.22N/AN/A$4.04 per share0.01REVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/AHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%8/11/2025 (Estimated)PTPIPetros Pharmaceuticals-$8.16M-$119.00N/A∞N/AN/A-78.22%-23.50%N/AREVBRevelation Biosciences-$15.04M-$102.61N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)Latest BON, PTPI, HEPA, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PTPIPetros PharmaceuticalsN/A-$8.46N/A-$9.37N/AN/A5/8/2025Q1 2025REVBRevelation Biosciences-$6.88-$2.11+$4.77-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBONBon Natural LifeN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBONBon Natural Life0.022.422.32HEPAHepion PharmaceuticalsN/A1.301.30PTPIPetros Pharmaceuticals1.580.850.74REVBRevelation BiosciencesN/A3.603.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBONBon Natural Life0.57%HEPAHepion Pharmaceuticals17.24%PTPIPetros Pharmaceuticals12.34%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipBONBon Natural Life26.48%HEPAHepion Pharmaceuticals0.06%PTPIPetros Pharmaceuticals12.25%REVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBONBon Natural Life100167,000863,000Not OptionableHEPAHepion Pharmaceuticals2010.93 million6.63 millionNo DataPTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableREVBRevelation Biosciences10960,000942,000Not OptionableBON, PTPI, HEPA, and REVB HeadlinesRecent News About These CompaniesRevelation Biosciences Inc News (REVB) - Investing.comJune 24, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 29, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comREVB On Track and Exploring New MarketsMay 9, 2025 | msn.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, ...May 8, 2025 | gurufocus.comRevelation Biosciences to Develop Gemini for Infection in Severe Burn PatientsApril 29, 2025 | businesswire.comWhy Revelation Biosciences Inc. (REVB) Went Down On Thursday?April 10, 2025 | msn.comGemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear CellsMarch 17, 2025 | businesswire.comRevelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceMarch 13, 2025 | businesswire.comRevelation Biosciences reports Q4 EPS ($4.98) vs ($133.64) last yearMarch 8, 2025 | markets.businessinsider.comRevelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD PatientsFebruary 26, 2025 | businesswire.comRevelation Biosciences, Inc. Receives Continued NASDAQ Listing ApprovalFebruary 24, 2025 | businesswire.comREVB Start 1B Trial and Announces SplitJanuary 29, 2025 | msn.comRevelation Biosciences Inc trading halted, news pendingJanuary 27, 2025 | markets.businessinsider.comRevelation Biosciences announces 1-for-16 reverse stock splitJanuary 24, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden Dome3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherThe Market’s Silent Warning: What Bonds and Gold RevealBy Gabriel Osorio-Mazilli | June 6, 2025View The Market’s Silent Warning: What Bonds and Gold RevealSuper Micro’s Bold $2B Bond Plan Signals 35% Premium UpsideBy Gabriel Osorio-Mazilli | June 26, 2025View Super Micro’s Bold $2B Bond Plan Signals 35% Premium UpsideBON, PTPI, HEPA, and REVB Company DescriptionsBon Natural Life NYSE:BON$1.26 -0.11 (-8.03%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.28 +0.02 (+1.98%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Hepion Pharmaceuticals NASDAQ:HEPA$0.07 0.00 (-6.40%) As of 06/27/2025 03:07 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Petros Pharmaceuticals NASDAQ:PTPI$0.04 +0.00 (+5.99%) As of 06/27/2025 03:59 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Revelation Biosciences NASDAQ:REVB$0.76 -0.06 (-7.44%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.75 -0.01 (-1.71%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
